Telix Pharmaceuticals (ASX:TLX) shares fell 3% in recent Monday trade after the company said late Friday it has entered into letters of intent to pursue collaborations with EDAP TMS and Profound Medical, developers of minimally invasive and image-guided ablative treatment technologies for prostate cancer.
The company said in a statement that the collaborations will explore the investigational use of its prostate-specific membrane antigen positron emission tomography imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound and other image-guided therapies designed to treat localized prostate cancer, including transurethral ultrasound ablation.